Takafumi Togashi
Overview
Explore the profile of Takafumi Togashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Omata J, Ueki Y, Takahashi Y, Tanaka R, Yokoyama Y, Takahashi T, et al.
Laryngoscope
. 2024 May;
134(9):E30.
PMID: 38757672
No abstract available.
2.
Tanaka R, Ueki Y, Ohshima S, Omata J, Yokoyama Y, Takahashi T, et al.
Int J Clin Oncol
. 2024 May;
29(8):1133-1141.
PMID: 38727853
Background: As a substantial waiting time is usually required for radical surgery, safe and effective preoperative neoadjuvant chemotherapy (NAC) is desired for the treatment of locally advanced head and neck...
3.
Ueki Y, Ohshima S, Yokoyama Y, Takahashi T, Shodo R, Yamazaki K, et al.
Int J Clin Oncol
. 2023 Oct;
29(1):20-26.
PMID: 37843751
Background: The optimal chemotherapy regimen in concurrent chemoradiotherapy (CCRT) for cisplatin-ineligible head and neck squamous cell carcinoma (HNSCC) has not been established. We aimed to evaluate the feasibility, efficacy, and...
4.
Omata J, Ueki Y, Takahashi Y, Tanaka R, Yokoyama Y, Takahashi T, et al.
Laryngoscope
. 2023 Sep;
134(4):1679-1686.
PMID: 37698411
Objective: Recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) treatment has changed dramatically with the introduction of immune checkpoint inhibitors (ICIs). However, there are few reports of treatment outcomes on...
5.
Hirai H, Nakaguro M, Tada Y, Saigusa N, Kawakita D, Honma Y, et al.
Virchows Arch
. 2023 Jul;
483(3):367-379.
PMID: 37464232
Salivary duct carcinoma (SDC) is an aggressive type of salivary gland carcinoma. Recently, immunotherapies targeting immune checkpoints, including PD1, PD-L1, CTLA4, and LAG3, have had a considerable prognostic impact on...
6.
Ohshima S, Ueki Y, Yokoyama Y, Takahashi T, Shodo R, Yamazaki K, et al.
Front Surg
. 2023 Apr;
9:1032626.
PMID: 37082097
Background: Head and neck mucosal melanoma (HNMM) is a rare and aggressive subtype of melanoma. HNMM often develops as a recurrent or metastatic disease, and its prognosis is worse than...
7.
Otaki K, Takahashi T, Tanaka R, Saijo K, Omata J, Yokoyama Y, et al.
Front Surg
. 2023 Jan;
9:1035349.
PMID: 36589621
Objective: The global standard for chemoradiation therapy (CCRT) for head and neck squamous cell carcinoma is cisplatin 100 mg/m administered once every three weeks, although cisplatin 80 mg/m is also...
8.
Matsuyama H, Ueki Y, Okamoto I, Nagao T, Honda K, Yamazaki K, et al.
Front Surg
. 2022 Dec;
9:1049116.
PMID: 36451679
Objective: Basal information of head and neck small-cell carcinoma (HNSmCC) including epidemiology, primary site, treatment, and prognosis remains sparse due to its rarity. We report here a multicenter retrospective study...
9.
Kohsaka S, Tada Y, Ando M, Nakaguro M, Shirai Y, Ueno T, et al.
NPJ Precis Oncol
. 2022 Nov;
6(1):82.
PMID: 36333410
Molecular targets and predictive biomarkers for prognosis in salivary duct carcinoma (SDC) have not been fully identified. We conducted comprehensive molecular profiling to discover novel biomarkers for SDC. A total...
10.
Kawakita D, Nagao T, Takahashi H, Kano S, Honma Y, Hirai H, et al.
Ther Adv Med Oncol
. 2022 Sep;
14:17588359221119538.
PMID: 36090801
Background: The efficacy and safety of human epidermal growth factor receptor 2 (HER2)-targeted therapy and androgen deprivation therapy (ADT) for locally advanced or recurrent or metastatic (LA/RM) salivary duct carcinoma...